JP2024528097A - 上気道における微生物感染の治療のためのペプチダーゼ製剤 - Google Patents

上気道における微生物感染の治療のためのペプチダーゼ製剤 Download PDF

Info

Publication number
JP2024528097A
JP2024528097A JP2024505421A JP2024505421A JP2024528097A JP 2024528097 A JP2024528097 A JP 2024528097A JP 2024505421 A JP2024505421 A JP 2024505421A JP 2024505421 A JP2024505421 A JP 2024505421A JP 2024528097 A JP2024528097 A JP 2024528097A
Authority
JP
Japan
Prior art keywords
composition
composition according
virus
glycerol
trypsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505421A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528097A5 (enExample
Inventor
クラーサンド，マッツ
Original Assignee
ジーミキュー テクノロジー アクチエボラグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーミキュー テクノロジー アクチエボラグ filed Critical ジーミキュー テクノロジー アクチエボラグ
Publication of JP2024528097A publication Critical patent/JP2024528097A/ja
Publication of JP2024528097A5 publication Critical patent/JP2024528097A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024505421A 2021-08-03 2022-08-03 上気道における微生物感染の治療のためのペプチダーゼ製剤 Pending JP2024528097A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21189429 2021-08-03
EP21189429.0 2021-08-03
PCT/EP2022/071842 WO2023012224A1 (en) 2021-08-03 2022-08-03 Peptidase formulation for treatment of microbial infections in the upper respiratory tract

Publications (2)

Publication Number Publication Date
JP2024528097A true JP2024528097A (ja) 2024-07-26
JP2024528097A5 JP2024528097A5 (enExample) 2025-08-07

Family

ID=77207007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505421A Pending JP2024528097A (ja) 2021-08-03 2022-08-03 上気道における微生物感染の治療のためのペプチダーゼ製剤

Country Status (5)

Country Link
US (1) US20240173387A1 (enExample)
EP (1) EP4380549B1 (enExample)
JP (1) JP2024528097A (enExample)
CN (1) CN117794513A (enExample)
WO (1) WO2023012224A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599883B1 (en) * 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
CN100584376C (zh) * 2006-05-25 2010-01-27 广西亚热带作物研究所 治疗深度带痂糜烂性创伤的药物
EP3121272A1 (en) * 2015-07-24 2017-01-25 Zymetech ehf. Novel fish trypsin isoforms and their use
GB201800274D0 (en) * 2018-01-08 2018-02-21 Enzymatica Ab Novel treatments
US11013687B1 (en) * 2020-06-08 2021-05-25 Amcyte Pharma, Inc. Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2

Also Published As

Publication number Publication date
CN117794513A (zh) 2024-03-29
WO2023012224A1 (en) 2023-02-09
EP4380549A1 (en) 2024-06-12
EP4380549B1 (en) 2024-11-13
EP4380549C0 (en) 2024-11-13
US20240173387A1 (en) 2024-05-30

Similar Documents

Publication Publication Date Title
AU2016293004B2 (en) Stuffy nose deblocking composition having antiviral activity
ES3058227T3 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
US20170216323A1 (en) Methods for Treating Viral Infections Using Hydrogen Sulfide Donors
RU2524304C2 (ru) Применение соли ацетилсалициловой кислоты для лечения вирусных инфекций
US20160058779A1 (en) Methods for treating viral infections using hydrogen sulfide donors
US8709496B2 (en) Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract
TW202200120A (zh) 鼻內給藥的聚合性組合物
US11826382B2 (en) Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
JP7821168B2 (ja) 感染を防止するための組成物
CN116056714A (zh) 预防冠状病毒及/或呼吸道融合病毒感染的方法
US11642372B2 (en) Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
JP2024528097A (ja) 上気道における微生物感染の治療のためのペプチダーゼ製剤
NZ532019A (en) Anti-influenza drugs
US20230218557A1 (en) A fatty acid based composition for treatment and/or prevention of enveloped-virus related infections
US20230218667A1 (en) THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES
BR112021009572A2 (pt) métodos e composições para prevenção ou tratamento de exacerbações agudas com imunoglobulina policlonal
WO2023046680A1 (en) Combination of cetylpyridinium and benzydamine with virucidal effect on sars-cov-2
CN102369012B (zh) 氧化氘用于治疗病毒性呼吸道疾病的用途
WO2021236626A1 (en) Mucoretentive antiviral technologies
WO2022046668A1 (en) Compositions and methods for reducing the transmissivity of illnesses
Pujarern et al. Lesson Learned from Antiseptic Mouthwash in COVID-19 Pandemic Then, Now and Future: A Systematic Review
US12485093B2 (en) Composition for use as an antiviral in the form of nasal drops and in nebulisers
TWI836258B (zh) 預防冠狀病毒及/或呼吸道融合病毒感染的方法
US20220362190A1 (en) Viral inactivation spray and gargling formulation
US20250032598A1 (en) Compounds, Pharmaceuticals, Formulations, and Methods for Treating and Preventing RNA Virus Infections and Associated Diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250729